This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Miltenyi Biotec B.v. Co., Kg, Novartis Ag. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Nina Moker - Innovator in Cellular Biotechnology
Introduction
Nina Moker is a prominent inventor based in Cologne, Germany. She has made significant contributions to the field of cellular biotechnology, particularly in the area of natural killer (NK) cell research. With a total of 2 patents, her work has the potential to impact therapeutic approaches in immunology.
Latest Patents
Nina Moker's latest patents include a method for NK cell transduction. This invention discloses an in-vitro method for transferring biological material into activated NK cells using a pseudotyped retroviral vector particle or a virus-like particle. The process involves the activation of NK cells followed by the addition of the vector particle, which comprises a modified baboon endogenous retrovirus envelope glycoprotein. This innovation allows for effective binding and fusion with hematopoietic cell membranes, facilitating the transfer of biological material into the activated NK cells. Additionally, she has developed anti-betacellulin antibodies and multi-specific binding molecules, which include bispecific antibodies that target both BTC and VEGF.
Career Highlights
Throughout her career, Nina has worked with notable companies such as Miltenyi Biotec and Novartis. Her experience in these organizations has contributed to her expertise in biotechnology and immunology.
Collaborations
Nina has collaborated with esteemed colleagues, including Ana Maria Carrion and Kirk Lee Clark. These partnerships have further enriched her research and development efforts in the field.
Conclusion
Nina Moker is a trailblazer in the realm of cellular biotechnology, with her innovative patents paving the way for advancements in immunotherapy. Her contributions are poised to make a lasting impact on the scientific community and beyond.